Belay Diagnostics Partners with GenomOncology for Enhanced Cancer Detection
Belay Diagnostics is excited to share its recent partnership with GenomOncology, a leader in precision medicine software. This collaboration aims to enhance the effectiveness of Belay's innovative Summit™ test and comprehensive DNA panel, particularly for the tertiary analysis of their advanced liquid biopsy methodologies. The integration of GenomOncology's Pathology Workbench into Belay's workflow represents a significant advancement in the realm of cancer detection, specifically targeting central nervous system (CNS) cancers.
Transforming Cancer Diagnostics with Innovative Solutions
At the heart of this partnership is the Summit™ test, a cutting-edge assay that plays a crucial role in diagnosing and managing both primary and secondary CNS malignancies. This fundamental test is designed to detect a myriad of genetic variations, including single nucleotide and multi-nucleotide variants as well as insertions, deletions, and chromosome level alterations linked to CNS tumors. The result is a enhanced diagnostic prowess, offering vital information for treatment pathways.
Introducing the Vantage™ Test
Alongside Summit™, Belay Diagnostics has developed another innovative solution: the Vantage™ test. Tailored to ascertain the methylation status of the MGMT promoter in cerebrospinal fluid (CSF), this test compliments the Summit™ by providing critical data that enhances decision-making in clinical settings. Remarkably, both tests can be conducted simultaneously with just a 6mL sample of CSF, greatly simplifying the testing process for healthcare providers.
Collaboration Benefits and Efficiency Gains
With the incorporation of the GO Pathology Workbench, the team at Belay Diagnostics has the capability to analyze thousands of samples every month with higher accuracy and efficiency. This innovative platform not only streamlines the variant analysis process but also empowers specialists to provide prompt and accurate treatment recommendations. Dr. Honey Reddi, a key figure at Belay, emphasizes that this collaboration optimizes lab overhead, enabling quicker access to vital insights for patients.
Enhancing Patient Care Through Education
To further expand understanding of these advancements, Dr. Reddi will be conducting a webinar titled "Belay Summit™ + GenomOncology - Maximizing Clinical Utility to Inform Diagnosis of CNS Tumors." The session is designed to educate healthcare providers about the innovative capabilities of these tests and will highlight how they can transform patient management strategies.
Insight into GenomOncology's Role
GenomOncology, known for its sophisticated software solutions, provides invaluable resources that amplify the capabilities of Belay's assays. According to GenomOncology's Chief Commercial Officer, Garreth Hippe, the flexibility of their Pathology Workbench allows tailoring specific features to align with Belay Diagnostics' unique testing requirements. This adaptability is key in enhancing turnaround times and ensuring detailed variant interpretations.
Understanding the Pathology Workbench
The GO Pathology Workbench offers a comprehensive solution for variant analysis, significantly easing the interpretation and reporting processes. It generates customized outputs that can seamlessly integrate into existing laboratory information systems or electronic health records. This versatility makes it an essential component for modern laboratories aiming to optimize their workflows and improve patient outcomes.
About GenomOncology
GenomOncology stands as a pioneering force in precision medicine, providing essential tools for the healthcare community. Their mission revolves around transforming complex data into actionable treatment options, thus enabling personalized cancer care. Their comprehensive set of software solutions enhances decision support, combining various data resources with internal patient information to optimize outcomes.
About Belay Diagnostics
Belay Diagnostics is dedicated to improving patient health through advanced diagnostic options. Their Summit™ and Vantage™ tests for CNS tumors are designed to inform clinical decisions and therapeutic strategies. With a rapid turnaround time of 7 to 10 days from specimen receipt, Belay stands at the forefront of precision oncology.
Frequently Asked Questions
What is the purpose of the Summit™ test?
The Summit™ test is a liquid biopsy assay that aids in the diagnosis and management of CNS tumors by detecting various genetic mutations in a patient's samples.
How does the partnership with GenomOncology benefit Belay Diagnostics?
This collaboration enhances the efficiency of variant interpretation and analysis workflows, allowing for quicker and more accurate treatment recommendations for patients.
What is the significance of the Vantage™ test?
The Vantage™ test determines the methylation status of the MGMT promoter in CSF, providing critical information that informs treatment decisions for CNS tumors.
Where can healthcare providers learn more about the new testing options?
Providers can attend the upcoming webinar hosted by Dr. Honey Reddi to gain insights and further education on these advanced diagnostic tests.
What is the turnaround time for the tests offered by Belay Diagnostics?
Belay Diagnostics offers a prompt turnaround of 7 to 10 days from receipt of specimens for their tests.
